Advances in Type 1 Diabetes Technology Over the Last Decade
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The past 10 years have witnessed rapid advances in the technology used to treat patients with type 1 diabetes (T1D). While the disease burden is still high, these advances have contributed to improvements in both glycaemic control and quality of life for many of those affected. New technologies allow for individualisation of care, as patients are able to work with their providers to determine which systems best fit their lifestyle and needs. In addition, thanks to improved glucose monitoring technologies, patients can now simultaneously improve glycaemic control and reduce hypoglycaemia, thereby mitigating risk for acute and chronic complications. Technological advances in T1D care are rapidly moving us toward increasingly automated devices, which offer the promise of reduced disease burden. In this article, we review advances in glucose monitoring, insulin and glucagon delivery, and the applications and algorithms seeking to integrate novel technologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 3×
“CGMs provide the benefits of improved control, decreased time spent in hyper or hypoglycaemia, and optimally, decreased risk of complications secondary to T1D.(5,6) CGMs have been associated with the most substantial improvement in glycated haemoglobin (HbA1c) in patients who had a higher baseline HbA1c and in those w…”
BackgroundInfluentialThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 3×
“It also introduced the threshold suspend function, which used SmartGuard™ technology to suspend basal insulin for up to 2 hours if the patient did not respond to a low glucose alert.11 This feature was shown to reduce night-time hypoglycaemia without increasing HbA1c.33 Medtronic has discontinued production of these l…”
BackgroundGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585 · cited 3×
“There were no episodes of DKA or severe hypoglycaemia in this study.(36) Thousands of hours of real-world data have confirmed the findings in the pivotal study.”
BackgroundMethodInfluentialPickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541 · cited 1×
“15%.(7) Each of these systems requires a sensor that is inserted subcutaneously and measures interstitial fluid glucose values; data are then relayed to a transmitter.”
BackgroundForlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246 · cited 1×
“Therefore time in range from 70–180 mg/dL increased slightly from 64% to 65%.(41) T:slim X2 users who also wear the Dexcom G6 are not required to perform finger-sticks for calibrations or insulin delivery.”
BackgroundWhat do we know about mobile applications for diabetes self-management? A review of reviews
Hood, M., Wilson, R., Corsica, J., Bradley, L., Chirinos, D., & Vivo, A. (2016) · Journal of Behavioral Medicine · doi:10.1007/s10865-016-9765-3 · Cited by 161
Hövelmann, U., Bysted, B. V., Mouritzen, U., Macchi, F., Lamers, D., Kronshage, B., Møller, D. V., & Heise, T. (2018) · Diabetes Care · doi:10.2337/dc17-1402 · Cited by 115 · cited 1×
“Phase II trials have been completed and demonstrated similar pharmacokinetics to current glucagon formulations with similar side effects of dosedependent nausea and vomiting.(50) Xeris (Chicago, Illinois, USA) has developed a stable liquid glucagon that is a native human glucagon dissolved in a carrier solution, dimet…”
BackgroundYale, J.-F., Dulude, H., Egeth, M., Piché, C. A., Lafontaine, M., Carballo, D., Margolies, R., Dissinger, E., Shames, A. R., Kaplowitz, N., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0460 · Cited by 88 · cited 2×
“in which a hypoglycaemic episode was simulated, only 13% of caregivers and 0% of acquaintances were able to successfully deliver a full dose of glucagon, while three participants actually delivered insulin instead.(49) Newer formulations of glucagon including stable glucagon and intranasal glucagon are discussed below…”
BackgroundSmart pens will improve insulin therapy
Klonoff, D. C., & Kerr, D. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818759845 · Cited by 73 · cited 1×
“Barriers to compliance with insulin administration including inappropriate dosing and remembering to administer injections can be overcome with these devices.(28)”
Background
Cited by
Arffman, M., Hakkarainen, P., Keskimäki, I., Oksanen, T., & Sund, R. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110580 · Cited by 58
Is a Cloud-Based Platform Useful for Diabetes Management in Colombia? The Tidepool Experience
León-Vargas, F., Martin, C., Garcia-Jaramillo, M., Aldea, A., Leal, Y., Herrero, P., Reyes, A., Henao, D., & Gomez, A. M. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.106205 · Cited by 14
Amed, S., Pinkney, S., Abdulhussein, F. S., Virani, A., Zachariuk, C., Tamana, S. K., Muralidharan, S., Görges, M., Barrett, B., van Rooij, T., et al. (2025) · PLOS Digital Health · doi:10.1371/journal.pdig.0000861 · Cited by 1
Metadata
- Authors
- Zimmerman, C., University of Florida, G., Albanese-O’Neill, A., University of Florida, G., Haller, M. J., & University of Florida, G.
- Venue
- European Endocrinology
- Publisher
- Touch Medical Media, Ltd.
- Published
- 2019
- Volume
- 15
- Issue
- 2
- Pages
- 70
- ISSN
- 1758-3772 (ISSN-L)
- OpenAlex
- W2970298091
- Cited by
- 47
- References
- 9
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.